Thumbay Labs, a mainstay of the UAE’s lab industry that accounts for approximately one-fifth of the entire national market share, recently said it plans to open advanced testing facilities, widen its portfolio and further increase its production this year.
Along with conventional expansion methods such as teaming up with hospitals and stand-alone locations, the company’s strategy will focus on targeting specialized areas such as diabetology, genetics, women’s health and children’s health. Its NeoScreen patented product, for example, is a newborn screening device marketed at a competitive price in the emirates.
Thumbay Labs Director P. K. Menon said the company is seeking partners as it introduces newer technologies. Thumbay Labs is the only laboratory enterprise in the Northern Emirates with accreditation from the Washington, D.C.-based College of American Pathologists (CAP) and operates under the auspices of the Center for Advanced Biomedical Research and Innovation (CABRI) at the Gulf Medical University in Ajman.
"CABRI plays an important role in enhancing the quality of training for students undergoing master's degrees at Gulf Medical University,” Thumbay Moideen, who founded Thumbay Group in 1997 and serves as president, said. “It also plays important part in enhancing student/faculty research and coordinates contracted research through Thumbay Group’s hospitals."
The company, which also operates lab facilities in Hyderabad, India, expects to open more clinical outlets in the near future to accommodate imaging, cardiology and neurology testing, occupational health assessments, allergy evaluations and preventive health initiatives.